<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04150341</url>
  </required_header>
  <id_info>
    <org_study_id>0178</org_study_id>
    <secondary_id>2019-002915-24</secondary_id>
    <nct_id>NCT04150341</nct_id>
  </id_info>
  <brief_title>Effect of Inhaled TD-8236 on Allergen-induced Asthmatic Response</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, 3-period Crossover Study to Evaluate the Effects of Repeated Doses of Inhaled TD-8236 and Impact on Airway Responses Following Allergen Challenge in Patients With Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theravance Biopharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theravance Biopharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a randomized, double-blind, placebo-controlled study. The study will use a
      three-period, six-sequence, complete-block, cross-over study design to characterize two doses
      of inhaled TD-8236 compared to placebo in subjects with mild asthma and a known response to
      an allergen. Each of the three periods will be 14 days, followed by a washout period before
      the next period.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 29, 2019</start_date>
  <completion_date type="Anticipated">October 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC of absolute change in FEV1</measure>
    <time_frame>Baseline to Day 14 (3 to 8 hours after inhaled allergen challenge at Day 14)</time_frame>
    <description>Area under the curve (AUC) of absolute change from baseline in FEV1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC of percentage change in FEV1</measure>
    <time_frame>Baseline to Day 14 (3 to 8 hours after inhaled allergen challenge at Day 14)</time_frame>
    <description>Area under the curve (AUC) of percentage change from baseline in FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum absolute decline in FEV1</measure>
    <time_frame>Baseline to Day 14 (3 to 8 hours after inhaled allergen challenge at Day 14)</time_frame>
    <description>Maximum absolute decline in FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum percentage decline in FEV1</measure>
    <time_frame>Baseline to Day 14 (3 to 8 hours after inhaled allergen challenge at Day 14)</time_frame>
    <description>Maximum percentage decline in FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough</measure>
    <time_frame>Day 14</time_frame>
    <description>Trough concentration prior to dosing on Day 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Day 14</time_frame>
    <description>Maximum concentration after dosing on Day 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs</measure>
    <time_frame>Baseline through day 14 days</time_frame>
    <description>Frequency and severity of Adverse Events (AEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Laboratory Evaluations</measure>
    <time_frame>Baseline through day 14 days</time_frame>
    <description>Number of subjects with laboratory test abnormalities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs</measure>
    <time_frame>Baseline through day 14 days</time_frame>
    <description>Number of subjects with clinically significant vital sign abnormalities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECGs</measure>
    <time_frame>Baseline through day 14 days</time_frame>
    <description>Number of subjects with clinically significant ECG findings.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>TD-8236 Dose A (low dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TD-8236 Dose A (QD x 14 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TD-8236 Dose B (high dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TD-8236 Dose B (QD x 14 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (QD x 14 days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TD-8236</intervention_name>
    <description>The study drug will be administered by inhalation in the morning for 14 days during each period. A washout period of at least 21 days will exist between subsequent periods.</description>
    <arm_group_label>TD-8236 Dose A (low dose)</arm_group_label>
    <arm_group_label>TD-8236 Dose B (high dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo will be administered by inhalation in the morning for 14 days during each period. A washout period of at least 21 days will exist between subsequent periods.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, 18 to 65 years of age

          -  Willing and able to give informed consent and comply with study requirements

          -  Documented physician-diagnosed asthma for ≥ 4 months prior to Screening

          -  Body mass index (BMI) ≥ 18.0 and ≤ 35.0 kg/m2 at Screening and weighs ≥ 50 kg at
             Screening.

          -  Women of child bearing potential must have a negative pregnancy test

          -  Males and females must use a highly efficient birth control method

          -  Pre-bronchodilator FEV1 ≥ 70% predicted

          -  Documented allergy to at least one common allergen

          -  Dual responder to inhaled bronchial challenges

          -  Additional inclusion criteria apply

        Exclusion Criteria:

          -  Positive for hepatitis A, B or C, HIV or tuberculosis

          -  Clinically significant abnormalities of laboratory evaluations

          -  Have abnormal ECG measurements

          -  Any sign of respiratory tract infection within 6 weeks of screening

          -  Have a current bacterial, parasitic, fungal or viral infection

          -  History of life-threatening asthma

          -  Uses or have used tobacco or nicotine-containing products within 6 months prior to
             screening

          -  Additional exclusion criteria apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Theravance Biopharma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Theravance Biopharma Call Center</last_name>
    <phone>1-855-633-8479</phone>
    <email>medinfo@theravance.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Theravance Biopharma Investigational Site</name>
      <address>
        <city>London</city>
        <zip>W1G 8HU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Theravance Biopharma Investigational Site</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 15, 2019</study_first_submitted>
  <study_first_submitted_qc>November 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2019</study_first_posted>
  <last_update_submitted>February 13, 2020</last_update_submitted>
  <last_update_submitted_qc>February 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TD-8236</keyword>
  <keyword>Asthma</keyword>
  <keyword>Proof of concept</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Theravance Biopharma, Inc. will not be sharing individual de-identified participant data or other relevant study documents.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

